%0 Journal Article
%A Martínez López, Joaquín
%A De La Cruz, Javier
%A Gil Manso, Rodrigo
%A Alegre Amor, Adrián
%A Ortiz, Javier
%A Llamas, Pilar
%A Martínez Díez, Yolanda
%A Hernández Rivas, José Ángel
%A González Gascón y Marín, Isabel
%A Benavente Cuesta, Celina
%A Estival Monteliu, Pablo
%A Jiménez Yuste, Víctor
%A Canales Albendea, Miguel Ángel
%A Bastos Oreiro, Mariana Beatriz
%A Kwon Kim, Mi
%A Valenciano, Susana
%A Callejas Charavia, Marta
%A López Jiménez, Javier
%A Herrera Puente, Pilar
%A Duarte, Rafael
%A Núñez Martín Buitrago, Lucía
%A Sánchez Godoy, Pedro
%A Jacome Yerovi, Cristina
%A Martínez Barranco, Pilar
%A García Roa, María
%A Escolano Escobar, Cristian
%A Matilla García, Arturo
%A Rosado Sierra, Belén
%A Aláez Usón, María Concepción
%A Quiroz Cervantes, Keina
%A Martínez Chamorro, Carmen
%A Pérez Oteyza, Jaime
%A Martos Martinez, Rafael
%A Herráez, Regina
%A González Santillana, Clara
%A Del Campo, Juan Francisco
%A Alonso, Arancha
%A Fuente, Adolfo de la
%A Pascual, Adriana
%A Bustelos Rodriguez, Rosalía
%A Sebrango, Ana
%A Ruiz Mediavilla, Elena
%A Marcheco-Pupo, Eriel Alexis
%A Grande, Carlos
%A Cedillo, Ángel
%A Lumbreras Bermejo, Carlos Juan
%A Arroyo Barea, Andrés
%A Casas Rojo, Jose Manuel
%A Calbacho Robles, Maria
%A Díez Martín, José Luis
%A García Suárez, Julio
%T COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
%D 2023
%@ 2072-6694
%U https://hdl.handle.net/20.500.14352/72298
%X Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.
%~